Philogen Quote - PHIL

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

18.25

Bid

18.25

Offer

18.95

Volume

2,190

18.55 Day's Range 19.00

16.50 52 Week Range 21.90

Market Cap

737.256M

Previous Close

18.70

Open

19.00

Last Trade

18.25

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

5,677

Shares Outstanding

40,397,605

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

25.12M

Net Profit

-6.16M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.philogen.com

Headquarters

Siena, Siena, Ita

Founded

Philogen Spa is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker PHIL. The last closing price for Philogen was 18.70 €. Over the last year, Philogen shares have traded in a share price range of 16.50 € to 21.90 €.

Philogen currently has 40,397,605 shares in issue. The market capitalisation of Philogen is 755.44 € million.

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients...

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by...

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to...

Philogen Announces Clinical Trial Collaboration with MSD

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii...

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in...

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University...

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical...

Philogen Provides Corporate Update

Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.2	1.108033241	18.05	19	17.4	10629	18.33534348	DE
4	0.3	1.6713091922	17.95	19	16.5	7180	17.9172144	DE
12	-0.45	-2.4064171123	18.7	19.75	16.5	5677	18.2726444	DE
26	-3.05	-14.3192488263	21.3	21.6	16.5	6906	19.34875214	DE
52	0.75	4.28571428571	17.5	21.9	16.5	8332	19.21204502	DE
156	4.49	32.6308139535	13.76	21.9	13	8488	17.04590238	DE
260	1.25	7.35294117647	17	21.9	12.6	11889	16.06162708	DE

PHIL - Frequently Asked Questions (FAQ)

What is the current Philogen share price?

The current share price of Philogen is 18.25 €

How many Philogen shares are in issue?

Philogen has 40,397,605 shares in issue

What is the market cap of Philogen?

The market capitalisation of Philogen is EUR 755.44M

What is the 1 year trading range for Philogen share price?

Philogen has traded in the range of 16.50 € to 21.90 € during the past year

What is the reporting currency for Philogen?

Philogen reports financial results in EUR

What is the latest annual turnover for Philogen?

The latest annual turnover of Philogen is EUR 25.12M

What is the latest annual profit for Philogen?

The latest annual profit of Philogen is EUR -6.16M

What is the registered address of Philogen?

The registered address for Philogen is PIAZZA LA LIZZA, 7, SIENA, SIENA, 53100

What is the Philogen website address?

The website address for Philogen is www.philogen.com

Which industry sector does Philogen operate in?

Philogen operates in the PHARMACEUTICAL PREPARATIONS sector

Symbol	Price	Vol.
1WECWEC Energy Group Inc	102.80 € (9.50%)	6
GROWGrowens Spa	3.93 € (9.17%)	87.94k
NEXINexi S.p.A.	5.052 € (8.83%)	27.31M
ESIGMEsi SPA	1.84 € (8.24%)	270.9k
1OKEOneok Inc	95.70 € (7.40%)	16
WAMB26Ambromobiliare SpA	0.0282 € (-47.87%)	9.81k
1FRVIAForvia SE	8.52 € (-21.69%)	477.83k
SGFSogefi Spa	2.02 € (-13.68%)	1.49M
WRDF25Redelfi SpA	1.30 € (-13.31%)	1.6k
1C3C3ai Inc	22.60 € (-13.08%)	700
TITTelecom Italia SpA	0.2701 € (0.37%)	142.23M
ISPIntesa Sanpaolo Spa	4.732 € (-0.43%)	120.53M
SPMSaipem Spa	2.20 € (-2.18%)	59.2M
ENELEnel Spa	7.047 € (0.86%)	39.65M
ENIEni Spa	13.848 € (-1.61%)	37.16M

Symbol

Price

Vol.

TITTelecom Italia SpA

0.2701 €

(0.37%)

142.23M

ISPIntesa Sanpaolo Spa

4.732 €

(-0.43%)

120.53M

SPMSaipem Spa

2.20 €

(-2.18%)

59.2M

ENELEnel Spa

7.047 €

(0.86%)

39.65M

ENIEni Spa

13.848 €

(-1.61%)

37.16M

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Philogen Spa (PHIL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Philogen Spa

Ask ADVFN Intelligence (AI)

PHIL Latest News

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Philogen Spa (PHIL) Share Price

Philogen Spa (PHIL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Philogen Spa

Ask ADVFN Intelligence (AI)

PHIL Latest News

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free